Geneticist Michael Snyder has tracked the expression of his genes for three years, focusing on changes in response to chronic or acute disease.
Much of what we know about the immune system comes from experiments conducted on mice. But lab mice are not little human beings. The two species are separated by both physiology and lifestyles. Stanford immunologist Mark Davis is calling on his colleagues to shift their research focus to people.
Hiding mRNA messages in CARTs — positively charged degradable vehicles —smuggles them across the cell membrane and can 'vaccinate' against cancer in mice.
Mapping the geography of the immune response in triple negative breast cancers predicts patient survival and sheds light onto new aspects of tumor biology.
A workaround avoids a common, dangerous side effect of gene therapy: an autoimmune reaction to the normal protein, which could improve gene therapy.
Scientists at Stanford find a biomarker for flu susceptibility, enabling predictions of if someone is going to fall ill to the virus after being exposed.
Older people are more susceptible to infection, cancer, and autoimmunity than younger people. This may be the result of our immune cells' receiving increasingly random marching orders as we age.
When associated with tumors, immune cells known as macrophages can be both good and bad: they can help cancer spread and curb its growth.
Rheumatoid arthritis and coronary artery disease share a common culprit: an important type of immune cell, called a macrophage, that has gone haywire. Stanford investigators have zeroed in on a molecular defect in macrophages' metabolic process that drives both disorders.
Many infectious diseases are marked by cyclical ups and downs. Stanford's David Schneider takes a creative approach to making sense of them.
